Adaptive Biotechnologies Corp at Morgan Stanley Global Healthcare Conference Transcript
Hey, everyone. Good morning. I'm Tejas Savant. I cover Life Sciences here at Morgan Stanley. Before we begin, for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your Morgan Stanley sales rep. So it's my pleasure this morning to host Adaptive. And speaking on behalf of the company, we have Chad Robins, CEO; and Tycho Peterson, my old boss, CFO. Thanks for joining us today guys.
Questions & Answers
Chad maybe just to set the stage, can you reflect on the last 4 years post IPO in terms of what's gone well relative to your expectations back in 2019? And where progress has perhaps been slower than you'd anticipated in terms of monetizing the value of what is still a proprietary and incredibly valuable immune medicine platform?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |